Medtronic PLC $MDT Position Increased by JB Capital LLC

JB Capital LLC grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 8.0% during the third quarter, Holdings Channel reports. The firm owned 137,615 shares of the medical technology company’s stock after acquiring an additional 10,152 shares during the quarter. JB Capital LLC’s holdings in Medtronic were worth $13,106,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Medtronic by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after purchasing an additional 310,684 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Medtronic by 2.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 21,275,850 shares of the medical technology company’s stock valued at $1,854,616,000 after purchasing an additional 595,549 shares during the period. Invesco Ltd. grew its stake in Medtronic by 3.9% during the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after buying an additional 666,557 shares during the last quarter. Finally, Norges Bank acquired a new stake in Medtronic in the second quarter worth $1,432,698,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Up 0.5%

Shares of MDT stock opened at $96.68 on Wednesday. Medtronic PLC has a 1 year low of $79.38 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The business’s fifty day moving average is $97.56 and its 200-day moving average is $93.92. The stock has a market cap of $123.94 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 2.53 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the business posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s payout ratio is currently 76.55%.

Analyst Upgrades and Downgrades

MDT has been the subject of several analyst reports. UBS Group boosted their price target on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday, November 19th. JPMorgan Chase & Co. raised their price target on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Truist Financial decreased their price objective on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Stifel Nicolaus boosted their price target on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, Wells Fargo & Company raised their price target on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).